Sales & Marketing Deep Dive: Commercialisation 2024 In this issue, we unpack Ozempic’s rise to superstar status and the risks associated with its off-label use.
News ASCO26: Revolution's 'grand slam' data in pancreatic cancer Revolution Medicines' pan-RAS(on) inhibitor daraxonrasib has delivered an unprecedented result in pancreatic cancer.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
